ARCHIVES

Adverse data from cancer prevention trial makes Merck withdraw Vioxx from market. Researchers discuss implications for other cancer prevention trials.

This article is from The Cancer Letter archive.

Vol. 30 No. 39 | October 15, 2004

Download PDF Visit The Full Archive

Related Articles

PDQ Used Mainly For Information To Public, Not Much By Non-Oncologists, Evaluation Finds

August 18, 1989

Task Force Issues Guidless on LDCT Lung Screening

January 10, 2014

ODAC Okays Photofrin for Obstructive Esophageal Cancer

September 23, 1994

FDA Approves Imaging System To Detect Cervical Pre-Cancer

March 31, 2006

In Brief: Chemical Carcinogenesis, Epidemiology Trail Viral Oncology In Budget Growth, Board Notes

November 7, 1980

Maxine Singer Wins Top SES Award

January 8, 1988